踝关节置换翻修术的生存率
该研究利用英国国家关节登记处与NHS Digital数据,分析228例踝关节置换翻修术患者的生存率、翻修原因及再手术情况。翻修TAA的1年生存率为95.4%(95%CI 91.6-97.5),3年为87.7%,5年为77.5%。翻修专用假体生存优于使用初次置换假体,多变量Cox回归未发现失败的危险因素。
要点
- 翻修踝关节置换术后1年生存率95.4%(95%CI 91.6-97.5),5年生存率77.5%(95%CI 66.9-85.0)。
- 翻修专用假体生存优于使用初次置换假体。
- 粗分析中骨水泥使用(HR 3.02,95%CI 1.13-8.09)和距初次手术时间(HR 0.67,95%CI 0.47-0.97)为失败的危险因素。
核心结论
- 翻修踝关节置换术具有较好的中期生存率和较低的再手术率。
- 新型模块化翻修假体相比使用传统初次置换假体,似乎改善了生存率。
研究设计与样本
- 研究联合国家关节登记处和NHS Digital数据,报告翻修踝关节置换术的生存率。
- 共纳入228例接受翻修踝关节置换术的患者,平均随访2.6年(SD 2.0)。
- 采用寿命表和Kaplan Meier图评估生存率,拟合Cox比例风险回归模型比较失败率。
主要发现
- 初始手术与翻修之间的平均时间为2.3年(SD 1.8)。
- 最常用的假体为Inbone,共81例患者使用。
- 29例(12.7%)失败;9例(3.9%)接受进一步翻修,19例(8.3%)行融合术,1例(0.4%)截肢。
- 翻修术后1年生存率95.4%(95%CI 91.6-97.5),3年87.7%(95%CI 81.9-91.7;n=124),5年77.5%(95%CI 66.9-85.0;n=57)。
- 50例患者(21.9%)接受进一步手术;19例(8.3%)在术后12个月内再手术。
关键数值与推荐
- 粗分析中失败的显著危险因素为使用骨水泥(HR 3.02,95%CI 1.13-8.09)和距初次手术时间(HR 0.67,95%CI 0.47-0.97)。
- 多变量Cox回归模型未发现失败的危险因素。
- 翻修专用假体生存优于使用初次置换假体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The number of revision total ankle arthroplasties (TAAs) which are undertaken is increasing. Few studies have reported the survival after this procedure. The primary aim of this study was to analyze the survival of revision ankle arthroplasties using large datasets. Secondary aims were to summarize the demographics of the patients, the indications for revision TAA, further operations, and predictors of survival. METHODS: The study combined data from the National Joint Registry and NHS Digital to report the survival of revision TAA. We have previously reported the failure rates and risk factors for failure after TAA, and the outcome of fusion after a failed TAA, using the same methodology. Survival was assessed using life tables and Kaplan Meier graphs. Cox proportional hazards regression models were fitted to compare failure rates. RESULTS: A total of 228 patients underwent revision TAA. The mean follow-up was 2.6 years (SD 2.0). The mean time between the initial procedure and revision was 2.3 years (SD 1.8). The most commonly used implant was the Inbone which was used in 81 patients. A total of 29 (12.7%) failed; nine (3.9%) patients underwent a further revision, 19 (8.3%) underwent a fusion, and one (0.4%) had an amputation. The rate of survival was 95.4% (95% confidence interval (CI) 91.6 to 97.5) at one year, 87.7% (95% CI 81.9 to 91.7; n = 124) at three years and 77.5% (95% CI 66.9 to 85.0; n = 57) at five years. Revision-specific implants had a better survival than when primary implants were used at revision. A total of 50 patients (21.9%) had further surgery; 19 (8.3%) underwent reoperation in the first 12 months. Cox regression models were prepared. In crude analysis the only significant risk factors for failure were the use of cement (hazard ratio (HR) 3.02 (95% CI 1.13 to 8.09)) and the time since the primary procedure (HR 0.67 (95% CI 0.47 to 0.97)). No risk factors for failure were identified in multivariable Cox regression modelling. CONCLUSION: Revision TAAs have good medium term survival and low rates of further surgery. New modular revision implants appear to have improved the survival compared with the use of traditional primary implants at revision.
引用
- Jennison T, Ukoumunne OC, Lamb S, et al. Survival of revision ankle arthroplasty. Bone Joint J. 2023. PMID: 37909151. doi:10.1302/0301-620X.105B11.BJJ-2023-0199.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。